ASH 2023 | AFM13 with cord blood-derived NK-cell therapy in patients with refractory CD30-positive lymphomas
Yago Nieto, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents results from a Phase I/II trial (NCT04074746) evaluating the safety profile and efficacy of cord blood-derived cytokine-induced natural killer (NK) cells followed by systemic AFM13, a CD30/CD16A bispecific antibody, in patients with refractory CD30+ lymphomas who were refractory to brentuximab vedotin. This treatment regimen yielded excellent tolerability, with robust overall survival (OS) and event-free survival (EFS) rates. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Affimed, Astra Zeneca, Secura Bio
